APA (7th ed.) Citation

AM, T., K, G., BS, A., R, M., A, A., C, W., . . . S, W. (2023). Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer immunology research, 11(7), 925. https://doi.org/10.1158/2326-6066.CIR-22-0444

Chicago Style (17th ed.) Citation

AM, Tsimberidou, et al. "Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer." Cancer Immunology Research 11, no. 7 (2023): 925. https://doi.org/10.1158/2326-6066.CIR-22-0444.

MLA (9th ed.) Citation

AM, Tsimberidou, et al. "Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer." Cancer Immunology Research, vol. 11, no. 7, 2023, p. 925, https://doi.org/10.1158/2326-6066.CIR-22-0444.